HemaChrome, a digital health startup that uses smartphone technology to noninvasively and instantly measure blood haemoglobin levels, won phase 1 of the National Institutes of Health's RADx Tech for Maternal Health Challenge, as per a news release.
During phase 1 of the challenge, HemaChrome received a cash prize and was vetted by NIH's panel of scientific, medical and business experts for technical and commercial viability. The win will allow HemaChrome access to NIH's in-house and in-kind support to speed the development, validation and commercialization of its technology.
The technology was developed by HemaChrome's founder and chief science officer, Young Kim.
HemaChrome meets twice a week with the NIH RADx team of experts as part of the process to proceed to phase 2 of the challenge.
“Conventional blood haemoglobin tests are usually conducted by invasive and expensive venous blood draws, which require sophisticated equipment, highly trained experts to run the tests and patients who must be present on-site with their health care provider. Our simple app is intended to eliminate these barriers and make these tests accessible to everyone, especially those in health care deserts, by allowing clinicians to conduct point-of-care, home-based and remote diagnostic tests on their patients at a fraction of the cost,” said Young Kim in a news release.
Young Kim's research about this technology has been published in several publications and peer-reviewed journals. He is preparing additional papers and conducting ongoing clinical studies.
Click here to read the original news story.